Myeloproliferative Disorders

被引：16

作者：

Meier, Brian ^{[1
]}

Burton, John H. ^{[2
]}

机构：

[1] Carilion Clin, Dept Emergency Med, 525 Janette Ave Southwest, Roanoke, VA 24016 USA

[2] Carilion Clin, Dept Emergency Med, POB 13367, Roanoke, VA 24033 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2017年 / 31卷 / 06期

关键词：

Myeloproliferative disorders; Essential thrombocythemia; PolycytheMia vera; Chronic myelogenous leukemia; Primary myelofibrosis; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; CHRONIC GRANULOCYTIC LEUKEMIA; WORLD-HEALTH-ORGANIZATION; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; PRIMARY MYELOFIBROSIS; MECHANISMS; PROGENITORS; THROMBOSIS;

D O I：

10.1016/j.hoc.2017.08.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The emergency providers generally encounters myeloproliferative disorders (MPNs) in 1 of 2 ways: as striking laboratory abnormalities of seeming unknown consequence, or in previously diagnosed patients presenting with complications. The course of patients with MPNs is highly variable, but major complications can arise. Emergent conditions related to hyper viscosity need to be recognized early and treated aggressively. Rapid hydration, transfusion, cytoreduction, and early hematology consultation can be lifesaving. Likewise, although management is not altered, a high index of suspicion for thrombotic complications is required in patients with known MPNs as these are a significant cause of morbidity and mortality.

引用

页码：1029 / +

页数：17

共 49 条

[1]

Adel G., 2013, J Hematol Thromb Dis, V1, P107

[2] A clonogenic common myeloid progenitor that gives rise to all myeloid lineages [J].

Akashi, K ;

Traver, D ;

Miyamoto, T ;

Weissman, IL .

NATURE, 2000, 404 (6774) :193-197

[3] Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) [J].

Barbui, Tiziano ;

Finazzi, Guido ;

Carobbio, Alessandra ;

Thiele, Juergen ;

Passamonti, Francesco ;

Rumi, Elisa ;

Ruggeri, Marco ;

Rodeghiero, Francesco ;

Randi, Maria Luigia ;

Bertozzi, Irene ;

Gisslinger, Heinz ;

Buxhofer-Ausch, Veronika ;

De Stefano, Valerio ;

Betti, Silvia ;

Rambaldi, Alessandro ;

Vannucchi, Alessandro M. ;

Tefferi, Ayalew .

BLOOD, 2012, 120 (26) :5128-5133

[4] Thrombosis in primary myelofibrosis: incidence and risk factors [J].

Barbui, Tiziano ;

Carobbio, Alessandra ;

Cervantes, Francisco ;

Vannucchi, Alessandro M. ;

Guglielmelli, Paola ;

Antonioli, Elisabetta ;

Alvarez-Larran, Alberto ;

Rambaldi, Alessandro ;

Finazzi, Guido ;

Barosi, Giovanni .

BLOOD, 2010, 115 (04) :778-782

[5]

BEDI A, 1994, BLOOD, V83, P2038

[6] Hematopoietic growth factors [J].

Bociek, RG ;

Armitage, JO .

CA-A CANCER JOURNAL FOR CLINICIANS, 1996, 46 (03) :165-+

[7] Mechanisms of disease: The myeloproliferative disorders [J].

Campbell, Peter J. ;

Green, Anthony R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2452-2466

[8] New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment [J].

Cervantes, Francisco ;

Dupriez, Brigitte ;

Pereira, Arturo ;

Passamonti, Francesco ;

Reilly, John T. ;

Morra, Enrica ;

Vannucchi, Alessandro M. ;

Mesa, Ruben A. ;

Demory, Jean-Loup ;

Barosi, Giovanni ;

Rumi, Elisa ;

Tefferi, Ayalew .

BLOOD, 2009, 113 (13) :2895-2901

[9] How I treat newly diagnosed chronic phase CML [J].

Cortes, Jorge ;

Kantarjian, Hagop .

BLOOD, 2012, 120 (07) :1390-1397

[10] SOME SPECULATIONS ON THE MYELOPROLIFERATIVE SYNDROMES [J].

DAMESHEK, W .

BLOOD, 1951, 6 (04) :372-375

← 1 2 3 4 5 →